8 DECEMBER 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Grant of Options and PDMR Dealing
Oncimmune Holdings plc (AIM: ONC.L), a leading autoantibody profiling company to the pharmaceutical and biotechnology industry, today announces that as part of its management incentivisation scheme, options ("Options") to subscribe for 105,263 ordinary shares of £0.01 each in the Company ("Ordinary Shares") were granted on 8 December 2023 to Martin Hudson, Finance Director.
Following this grant, Mr Hudson holds Options over a total of 105,263 Ordinary Shares, representing approximately 0.14 per cent of the Company's issued share capital of 74,142,147. Other than the grant of the Options, neither Mr Hudson nor any of his connected persons have any beneficial interest in Ordinary Shares.
The Options have been granted under the Oncimmune Holdings Plc 2016 Unapproved and EMI Share Option Plan, have an exercise price of £0.266, being the closing price of Ordinary Shares on 7 December 2023, and vest annually in five equal parts from the date of grant until the fifth anniversary of the grant.
This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the UK Market Abuse Regulation.
Notification and public disclosure of transactions by person discharging managerial responsibilities and persons closely associated with them.
| 1
| Details of the person discharging managerial responsibilities / person closely associated
| ||||
| a)
| Name
| Mr Martin Hudson | |||
| 2
| Reason for the notification
| ||||
| a)
| Position/status
| Finance Director | |||
| b)
| Initial notification /Amendment
| Initial Notification | |||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| ||||
| a)
| Name
| Oncimmune Holdings plc | |||
| b)
| LEI
| 213800HCYIWT6YPI1I02 | |||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| ||||
| a)
| Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | |||
| | | ||||
| Identification code | ISIN: GB00BYQ94H38 | ||||
| | | ||||
| b)
| Nature of the transaction
| Grant of options | |||
| c)
| Price(s) and volume(s) | | | | |
| | | Price(s) | Volume(s) | | |
| | | £0.266 | 105,263 | | |
| | | | | | |
| d)
| Aggregated information | N/A - single transaction | |||
| | | ||||
| - Aggregated volume | | ||||
| | | ||||
| - Price | | ||||
| | | ||||
| e)
| Date of the transaction | 8 December 2023 | |||
| f) | Place of the transaction | Outside a trading venue
| |||
For further information:
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a global leader in immune biomarkers and immunodiagnostics, offering autoantibody biomarker profiling in immunooncology, autoimmune and infectious diseases. Through its ImmunoINSIGHTS™ technology platform, the Company provides insights and analytics to discover and validate novel biomarkers, improve treatment responses and adverse event (irAE) prediction, patient screening and diagnostic accuracy.
Oncimmune is headquartered in the UK, with its discovery and development facility based in Dortmund, Germany and a business development team based in the US and Europe.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
